Marksans Pharma Surges On FDA Nod For New Drug

• Marksans Pharma shares surged as much as 12.5 per cent to hit intraday high of Rs. 53.85 after the company announced that it has received US drug regulator's approval for a medicine used in treatment of sneezing, runny nose and other allergies.
• The Mumbai-based drugmaker in a statement issued to the stock exchange said, "USFDA has granted approval for an abbreviated new drug application (ANDA) for loratadine liquid filled capsules 10 mg."
• Loratadine liquid-filled capsules are therapeutically equivalent to the reference listed drug Claritin Liqui-Gels Capsules 10 mg of Bayer Healthcare LLC.  
• Loratadine is used to treat sneezing, runny nose, watery eyes, hives, skin rash, itching and other allergy symptoms.
• As of 11:11 a.m., Marksans Pharma shares traded 11 per cent higher at Rs. 53, outperforming the Nifty which was down 0.5 per cent.

Marksans, pharma surges, fda nod, new drug